Programs

Primary Indication

Preclin

Phase 1

Phase 2

Phase 3

RL-0071
Pro-cognitive neuromodulator

Cognitive Impairment Associated with Schizophrenia

Phase 2

Phase 2

VLS-01
DMT

Treatment Resistant Depression

Phase 1

Phase 1

EMP-01
R-MDMA

Social Anxiety Disorder

Phase 1

Phase 1

IBX-210
Ibogaine

Opioid Use Disorder

Phase 1

Phase 1

Novel 5-HT2A Receptor Agonists

Undisclosed

Preclin

Preclin

STRATEGIC INVESTMENTS

COMP3602
Psilocybin

Treatment Resistant Depression

Phase 3

Phase 3

BPL-0033
5-MeO-DMT

Treatment Resistant Depression

Phase 2

Phase 2

ELE-1013
Psilocin

Major Depressive Disorder

Phase 2

Phase 2

Abbreviations: DMT = N,N-Dimethyltryptamine; R-MDMA = R enantiomer of 3,4-Methyl​enedioxy​methamphetamine; 5-MeO-DMT = 5-methoxy-N,N dimethyltryptamine
1 Majority ownership stake in Recognify Life Sciences
2 Strategic Investment in Compass Pathways
3 Strategic Investment in Beckley Psytech

JOIN OUR MAILING LIST

Sign up to receive the latest news on atai.

Email
submit